Management of Systemic Manifestations of Fungal Gastrointestinal Infections

Diagnosis

Diagnosis of invasive fungal GI infections should be confirmed through appropriate cultures of infected fluid from the peritoneal cavity or affected GI tissues 2
Direct visualization through endoscopy with biopsy for histopathology and culture is essential for definitive diagnosis 3

Echinocandins are the preferred initial treatment for intra-abdominal candidiasis, particularly in critically ill patients, with options including Caspofungin, Micafungin, and Anidulafungin 1
Fluconazole 400 mg (6 mg/kg) daily may be used if the patient has no recent azole exposure and is not colonized with azole-resistant Candida species 1
Lipid formulation of Amphotericin B (3-5 mg/kg daily) can be considered if there is intolerance to other antifungal agents, though this carries higher toxicity risk 1

Treatment should continue for at least 2-3 weeks after resolution of symptoms and clearance of the infection 2
Follow-up cultures should be obtained to ensure clearance of the infection 1

Septic shock requires immediate echinocandin therapy along with aggressive fluid resuscitation and vasopressor support 2
Fungal peritonitis requires drainage of infected fluid along with systemic antifungal therapy 2

Source control with appropriate drainage and/or debridement is essential for successful treatment 1
Inadequate source control is associated with treatment failure regardless of appropriate antifungal therapy 1
Surgical intervention may be necessary for necrotic tissue removal or drainage of abscesses 2

After clinical improvement and culture results showing susceptible Candida species, consider step-down to oral fluconazole 400-800 mg daily 1
This transition should only occur after the patient has shown significant clinical improvement and is hemodynamically stable 1

Delaying antifungal therapy in suspected intra-abdominal fungal infections can significantly increase mortality 1
Using fluconazole empirically in critically ill patients without knowing Candida species susceptibility can lead to treatment failure 1
Premature discontinuation of therapy before complete resolution of infection 1
Failure to consider fungal infection in patients with persistent symptoms despite antibacterial therapy 4
Inadequate source control is a major cause of treatment failure 2

Patients with fungal GI infections often require nutritional support due to malabsorption and metabolic derangements 4
Parenteral nutrition may be necessary if the GI tract cannot be used 4